



# Financial Tear Sheet

## Corporate Profile

Over 45 million people in the U.S. have a substance use, addictive, or eating disorder. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases, which burden society at both the individual and community levels. Opiant is a specialty pharmaceutical company developing treatments for substance use, addictive, and eating disorders.

## Primary IR Contact

Sam Martin  
 Managing Director  
 Argot Partners  
 Phone: 212-600-1902  
 E-mail: [sam@argotpartners.com](mailto:sam@argotpartners.com)

## Stock Performance

### OPNT (Common Stock)

Exchange	OTC BB (US Dollar)
Financial Status Indicator	C
Price	\$5.77
Change (%)	▲ 0.30 (5.48%)
Volume	5,777
52 Week Low	\$5.00
Market Cap	\$11,085,546
Rolling EPS	2.51
PE Ratio	2.1826
Shares Outstanding	2,026,608

Data as of 06/26/17 4:00 p.m. ET



## Recent Headlines & Events

June 15, 2017 - 7:01 a.m.

[Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update](#)

March 27, 2017 - 7:01 a.m.

[Opiant Pharmaceuticals, Inc. Announces Results of Positron Emission Tomography \(PET\) Study of Naloxone Nasal Spray](#)

March 20, 2017 - 7:01 a.m.

[Opiant Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa](#)

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
06/14/17	10-Q
06/02/17	8-K
05/30/17	8-K
04/19/17	8-K

## Management Team

[Dr. Roger Crystal](#) Chief Executive Officer

[Kevin Pollack, Esq.](#) Chief Financial Officer

[Arvind Agrawal](#) Executive Vice President, Medical Affairs

[Mark Ellison](#) Executive Vice President Development, Manufacturing and Quality

Data provided by Nasdaq. Minimum 15 minutes delayed.